Načítá se...
Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients
BACKGROUND: Evidence on safety and effectiveness of omalizumab for treatment of chronic urticaria in pediatric patients is scarce and limited to case reports. In particular, drug survival of omalizumab has not yet been investigated, which is a key element in the evaluation of its clinical performanc...
Uloženo v:
| Vydáno v: | Pediatr Allergy Immunol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8248194/ https://ncbi.nlm.nih.gov/pubmed/33305439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pai.13426 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|